JP2019510812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510812A5 JP2019510812A5 JP2018563747A JP2018563747A JP2019510812A5 JP 2019510812 A5 JP2019510812 A5 JP 2019510812A5 JP 2018563747 A JP2018563747 A JP 2018563747A JP 2018563747 A JP2018563747 A JP 2018563747A JP 2019510812 A5 JP2019510812 A5 JP 2019510812A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- antibody
- polypeptide
- bdm
- molecule according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 101150099985 bdm gene Proteins 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022078237A JP2022105574A (ja) | 2016-02-26 | 2022-05-11 | 多重特異性分子 |
| JP2023219531A JP2024026531A (ja) | 2016-02-26 | 2023-12-26 | 多重特異性分子 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016900708A AU2016900708A0 (en) | 2016-02-26 | Multi-specific molecules 1 | |
| AU2016900709 | 2016-02-26 | ||
| AU2016900708 | 2016-02-26 | ||
| AU2016900709A AU2016900709A0 (en) | 2016-02-26 | Multi-specific molecules 2 | |
| PCT/AU2017/050168 WO2017143406A1 (en) | 2016-02-26 | 2017-02-27 | Multi-specific molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078237A Division JP2022105574A (ja) | 2016-02-26 | 2022-05-11 | 多重特異性分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510812A JP2019510812A (ja) | 2019-04-18 |
| JP2019510812A5 true JP2019510812A5 (enExample) | 2020-04-09 |
| JP7536424B2 JP7536424B2 (ja) | 2024-08-20 |
Family
ID=59685848
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563747A Active JP7536424B2 (ja) | 2016-02-26 | 2017-02-27 | 多重特異性分子 |
| JP2022078237A Pending JP2022105574A (ja) | 2016-02-26 | 2022-05-11 | 多重特異性分子 |
| JP2023219531A Pending JP2024026531A (ja) | 2016-02-26 | 2023-12-26 | 多重特異性分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078237A Pending JP2022105574A (ja) | 2016-02-26 | 2022-05-11 | 多重特異性分子 |
| JP2023219531A Pending JP2024026531A (ja) | 2016-02-26 | 2023-12-26 | 多重特異性分子 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20190338013A1 (enExample) |
| EP (1) | EP3419667A4 (enExample) |
| JP (3) | JP7536424B2 (enExample) |
| CN (1) | CN109310766A (enExample) |
| AU (2) | AU2017222700B2 (enExample) |
| TW (1) | TW201734037A (enExample) |
| WO (1) | WO2017143406A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017143406A1 (en) * | 2016-02-26 | 2017-08-31 | Imunexus Pty Ltd | Multi-specific molecules |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| MX2019013648A (es) | 2017-05-19 | 2021-01-08 | Wuxi Biologics Shanghai Co Ltd | Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4). |
| EP3668893A4 (en) * | 2017-08-16 | 2021-08-04 | Dragonfly Therapeutics, Inc. | PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1 |
| CN117050184A (zh) | 2017-12-28 | 2023-11-14 | 南京传奇生物科技有限公司 | 针对tigit的单域抗体和其变体 |
| TW201930349A (zh) * | 2018-01-08 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 多重特異性抗原結合蛋白及其使用方法 |
| JP7366908B2 (ja) | 2018-01-15 | 2023-10-23 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Ｐｄ－１に対する単一ドメイン抗体及びその変異体 |
| CA3090236A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| BR112021012631A2 (pt) | 2018-12-26 | 2021-12-14 | Xilio Dev Inc | Anticorpos anti-ctla4 e métodos de uso dos mesmos |
| KR20210131373A (ko) * | 2019-02-18 | 2021-11-02 | 커리어 테라퓨틱스, 인코포레이티드. | 오르토폭스바이러스 주요 조직적합성 복합체(mhc) 클래스 i-유사 단백질(omcp) 및 종양-특이 결합 파트너를 사용한 이중특이적 융합 단백질 |
| JP2022527761A (ja) * | 2019-03-26 | 2022-06-06 | フォーティ セブン， インコーポレイテッド | がん治療のための多重特異性作用物質 |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| EP4093745A4 (en) * | 2020-01-20 | 2024-03-06 | Wuxi Biologics Ireland Limited | NEW WASH BUFFER SOLUTION FOR AFFINITY CHROMATOGRAPHY |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| JP2023545135A (ja) * | 2020-10-12 | 2023-10-26 | グレフェックス， インコーポレイテッド | ＳＡＲＳ－ＣｏＶタンパク質発現細胞に対するＴ細胞応答を標的にする抗体コンストラクト、それらの設計および使用 |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| US20250345423A1 (en) * | 2021-11-26 | 2025-11-13 | Imunexus Therapeutics Limited | Binding domain molecules on cell surfaces |
| CN115078718B (zh) * | 2022-07-22 | 2024-11-12 | 福建师范大学 | 一种基于表面增强拉曼技术检测透明质酸酶的方法 |
| EP4615859A2 (en) * | 2022-11-09 | 2025-09-17 | Repligen Corporation | Affinity agents |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP221098A0 (en) * | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| EP1163339A1 (en) * | 1999-04-01 | 2001-12-19 | Innogenetics N.V. | A polypeptide structure for use as a scaffold |
| US20100081792A1 (en) * | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| DE112008003232T5 (de) * | 2007-11-30 | 2011-02-24 | Glaxo Group Limited, Greenford | Antigen-Bindungskonstrukte |
| HRP20180045T1 (hr) * | 2008-10-02 | 2018-03-23 | Aptevo Research And Development Llc | Proteini antagonisti cd86 koji se vežu na više meta |
| CA2763493A1 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Ltd. | Antigen-binding proteins |
| CN102458471A (zh) | 2009-05-28 | 2012-05-16 | 葛兰素集团有限公司 | 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合 |
| WO2017143406A1 (en) * | 2016-02-26 | 2017-08-31 | Imunexus Pty Ltd | Multi-specific molecules |
-
2017
- 2017-02-27 WO PCT/AU2017/050168 patent/WO2017143406A1/en not_active Ceased
- 2017-02-27 US US16/079,949 patent/US20190338013A1/en not_active Abandoned
- 2017-02-27 AU AU2017222700A patent/AU2017222700B2/en active Active
- 2017-02-27 EP EP17755659.4A patent/EP3419667A4/en active Pending
- 2017-02-27 CN CN201780024999.5A patent/CN109310766A/zh active Pending
- 2017-02-27 JP JP2018563747A patent/JP7536424B2/ja active Active
- 2017-03-01 TW TW106106646A patent/TW201734037A/zh unknown
-
2019
- 2019-01-02 AU AU2019200005A patent/AU2019200005A1/en not_active Abandoned
-
2020
- 2020-06-22 US US16/946,451 patent/US20210040177A1/en not_active Abandoned
-
2021
- 2021-04-06 US US17/223,935 patent/US11345736B2/en active Active
-
2022
- 2022-05-11 JP JP2022078237A patent/JP2022105574A/ja active Pending
-
2023
- 2023-08-28 US US18/239,052 patent/US20240182542A1/en active Pending
- 2023-12-26 JP JP2023219531A patent/JP2024026531A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510812A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| AR127371A2 (es) | Receptores quiméricos de flt3 y métodos para usarlos | |
| JP2020519643A5 (enExample) | ||
| JP2017184723A5 (enExample) | ||
| JP2019515646A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| JP2018172439A5 (enExample) | ||
| FI3515487T3 (fi) | Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja | |
| HK1207575A1 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
| JP2015146822A5 (enExample) | ||
| JP2018502050A5 (enExample) | ||
| PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
| NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| JP2016053091A5 (enExample) | ||
| PE20190911A1 (es) | Composiciones y anticuerpos anti-lag-3 | |
| PE20180693A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer epitelial de ovario y otros tipos de cancer | |
| JP2020500510A5 (enExample) | ||
| AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2017176174A5 (enExample) | ||
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| JP2014518883A5 (enExample) | ||
| HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä |